Therapeutics for metabolic diseases

14 important questions on Therapeutics for metabolic diseases

Conclude with the learning goals in mind:
✓ To gain insight into inherited neurometabolic disorders
✓ To delineate different therapeutic approaches
✓ To discuss a clinical case vignette
✓ Emma Center for Personalized Medicine
✓ Valorisation via 3FM Serious Request

There are a lot of them >1900. Less treatments available 15%.
...
The case vignette is about the pyridoxine dependent epilepsy. Treatment with supplements and knockout of the AASS enzyme.

Emma center focusses on the 4P's and collaborations also with the patient.

What type of genetic disorders are metabolic disorders? Leads to..?

Monogenic disorders -> 1 gen
Disrupted biochemical reaction pathway; pathway that is important for energy production.

What are implications of the diseases? (4) Name 3 symptoms. 2 organs mostly affected.

  • Energy deficiency & Shortage of building blocks
  • Accumulation of (toxic) substances
  • Children & adults; any organ(s) can be affected
  • Static but more often progressive symptoms


  1. epilepsy (neurometabolic)
  2. developmental delay
  3. movement disorders


  1. Brain (uses energy the most)
  2. Gut
  • Higher grades + faster learning
  • Never study anything twice
  • 100% sure, 100% understanding
Discover Study Smart

What is a key characteristic for metabolic disorders for therapy designing?

Small window of opportunity

What are the numbers
  • inherited metabolic diseases
  • how many in the screeningsprogram
  • % neurometabolic
  • % diagnostic success
  • % treatment succes

>1900
20
60%
70%
15%

What are different therapeutic approaches for IMDs?

Diet
Medicine => supplement, intervene on the pathway
Gene therapy

What is P4 medicine and how does this relate to IMD?

  1. Predictive: precise molecular diagnosis
  2. Preventive: disease modifying + targeted therapies
  3. Participatory: patient as partner
  4. Personalized: phenotype and function first + personalized outcomes

There are different kinds of interventions. From simple to innovative. Based on the pathway that is impaired. Name examples.

1. Limit a toxic intake => when you can not transform a toxic molecule.
2. Supplement tyrosine for example => in PKU
3. Other enzymes that potentially can do the same job
4. Provide a co-factor -> for transformation of molecules.
5. Hydroxylate enzyme -> to transform one amino acid into another.
6. Transplant an organ: for example, liver => too risky for PKU (phenylketonurie)
7. Stem cell, CRISPR.

What is the difference between RNA therapy and DNA therapy?

Difference between RNA therapy and gene therapy.
 provide the correct RNA => but it is a very temporary replacement so you must repeat it
 Gene therapy still has a long way to go. RNA therapy is more useful at the moment

Risk of DNA therapy is overcorrecting: meaning that gene replacement or gene silencing leads to an unphysiological (maybe neurotoxic) over- or underexpression of the healthy (endogenous or exogeneous) allele in a proportion of cells.

Currently difficult to predict expression levels when you deliver gene therapy.

What is the epidemiology of neonatal metabolic epilepsy? % treatable?

N=278
20% is treatable

What is the cause of pyridoxine-dependent epilepsy? (3)

  • Higher levels of P6C cause inactivation of PLP (B6). PLP is the active form of B6 => you need this to prevent seizures
  • Deficiëntie of enzym L-2-aminoadipate-6-semialdehyde (α-AASA)-dehydrogenase leads to increased α-AASA
  • Higher levels of pipecolic acid

P6C and AASA => are neurotoxic; intellectual disability

What is an example of (adjunct) therapy for pyridoxine-dependent epilepsy (PDE)?

Intra-cerebral lysine reduction therapy: (therapy on the first steps of the pathway)
  • protein restricted diet (no intake of lysine) & arginine supplementation to compensate for lysine
  • reduces neurotoxic metabolites
  • clinical effects…

What was the conclusion of the diet and supplements study? => clinically relevant

Starting before 6 months (in a child) saves 22 IQ points.

Describe a second example of adjunct therapy? How do we test this therapy?

Targeting inhibition of the AASS enzyme (inhibition of the lysine degradation) => leads to less AASS which is a neurotoxin.

Animal models: knockout model
Human models: neuronal models (organoids)

The question on the page originate from the summary of the following study material:

  • A unique study and practice tool
  • Never study anything twice again
  • Get the grades you hope for
  • 100% sure, 100% understanding
Remember faster, study better. Scientifically proven.
Trustpilot Logo